drugset / Trial / NCT04870190
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter, randomized controlled, double-blind clinical trial. The study is designed to evaluate the efficacy and safety of high-dose Almonertinib versus Osimertinib in the second-line treatment of patients with EGFR mutations in advanced NSCLC with brain metastases.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 165 mg | Oral |
| Comparator | Osimertinib | Small molecule | 80 mg | Oral |